Innate Immunotherapeutics Limited (ASX:IIL) has commenced patient dosing in its phase 2B trial of MIS416 for secondary progressive multiple sclerosis.
The biotech company says both its WA and Melbourne sites have dosed their first two patients with several more due to commence treatment this month.
The company has also announced the appointment of Dr Claudia Mansell as Senior Research Scientist to lead the analysis of trial subjects’ blood samples.
The company says the goal of the work is to develop tests that could be used to help monitor patients’ responses to treatment with MIS416.
Innate Immunotherapeutics reported a net loss of $4.49 million in the year to the end of March 2014.
